BioAtla Executive Compensation Details Revealed
Ticker: BCAB · Form: DEF 14A · Filed: Apr 24, 2025 · CIK: 1826892
Sentiment: neutral
Topics: executive-compensation, equity-awards, sec-filing
TL;DR
BioAtla dropped its 2024 exec comp details - check the equity awards and fair values.
AI Summary
BioAtla, Inc. filed a DEF 14A on April 24, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted, their fair value at vesting dates, and changes in fair value for outstanding awards. It also reports dividends or other earnings paid on equity awards not otherwise reflected in total compensation.
Why It Matters
This filing provides transparency into how BioAtla, Inc. compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but the details within can reveal significant information about a company's financial health and management practices.
Key Numbers
- 2024 — Reporting Year (Executive compensation data pertains to this fiscal year.)
- 2023 — Prior Year Data (Comparative data for equity awards and fair values from the previous year.)
- 2022 — Prior Year Data (Comparative data for equity awards and fair values from two years prior.)
Key Players & Entities
- BioAtla, Inc. (company) — Filer
- 0000950170-25-058011 (filing_id) — Accession Number
- 20250424 (date) — Filing Date
- 1231 (date) — Fiscal Year End
FAQ
What was the total compensation for the named executive officers in 2024?
The filing provides details on equity awards, their fair value changes, and dividends paid on awards, but does not explicitly state the total cash compensation for named executive officers for 2024 in the provided text.
What is the fair value of equity awards granted to executives in 2024?
The filing indicates that information regarding the year-end fair value of equity awards granted in the covered year (2024) and outstanding/unvested is included, but specific dollar amounts are not detailed in the provided text.
How did the fair value of outstanding equity awards change during 2024?
The filing mentions 'Change in Fr Val As Of Vstng Dt Of Prr Yr Eqty Awrds Vstd In Cvrd Yr' and 'Change in Fr Val Of Outsdng And Unvstd Eqty Awrds Grntd In Prr Yrs' for 2024, suggesting changes in fair value are reported.
Were there any dividends or other earnings paid on equity awards in 2023?
Yes, the filing includes a category for 'Dvdds Or Othr Erngs Pd On Eqty Awrds Nt Othrws Rflctd In Ttl Comp For Cvrd Yr' for the period ending December 31, 2023.
What is the company's primary business as indicated by the SIC code?
The company's Standard Industrial Classification (SIC) code is 2836, which corresponds to 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 24, 2025 regarding BioAtla, Inc. (BCAB).